Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2320193
下载链接
链接失效反馈官方服务：
资源简介：
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
创建时间：
2020-09-15
